Ultragenyx

Phase A — Understand the business

Lens 1 · Company Overview

Ultragenyx is a commercial-stage biopharmaceutical company built to develop and sell therapies for serious rare and ultra-rare genetic diseases — indications with clear, well-understood biology and, typically, no approved disease-modifying treatment. Founded April 2010 by Emil Kakkis, M.D., Ph.D. (still President & CEO), IPO'd 2014. The strategy is deliberately differentiated: in-license de-risked assets from academia/partners, retain global commercial rights, and run many small rare-disease programs in parallel — because each indication needs few patients and can ride accelerated/orphan regulatory paths, the portfolio diversifies binary risk across modalities (biologics, small molecules, AAV gene therapy, nucleic acids).

Four approved products generate the revenue:

• Crysvita (burosumab) — anti-FGF23 mAb for X-linked hypophosphatemia (XLH; ~48,000 patients in developed world) and tumor-induced osteomalacia (TIO). The franchise asset, partnered with Kyowa Kirin (KKC).
• Dojolvi (triheptanoin) — for long-chain fatty acid oxidation disorders.
• Evkeeza (evinacumab) — for homozygous familial hypercholesterolemia (licensed from Regeneron; ex-US/Japan markets).
• Mepsevii (vestronidase alfa) — enzyme replacement for MPS VII.

Revenue model has two distinct shapes:

1. Crysvita is a profit-share/royalty, not a self-sold product. Until April 2023 Ultragenyx and KKC split US-territory profits 50/50; since April 2023 KKC took over commercialization in the Profit-Share Territory and Ultragenyx now receives a tiered double-digit revenue share, "from the mid-20% range up to a max." That stream is the $304M "Crysvita royalty revenue" line. Ultragenyx also directly books Crysvita product sales only where it commercializes itself — Latin America and Türkiye (~$177M product line, growing on LatAm patient adds).
2. Dojolvi/Evkeeza/Mepsevii are fully owned product sales booked at 100%.

Customers are effectively national payers and specialty-pharmacy channels across North America, EU, UK, LatAm, Türkiye, Japan, and select markets, sold through its own specialized rare-disease commercial org plus third-party distributors in small markets. Key suppliers are contract manufacturers (CMOs) plus an internal gene-therapy manufacturing facility. customers.csv is empty — no concentration table on disk.

Plain-terms read: Crysvita is a maturing cash annuity that Ultragenyx no longer fully owns the upside of (revenue-share, much of it already sold forward — see Lens 10), funding a high-burn late-stage pipeline that is the actual equity story.

Lens 2 · Supply Chain

Map: academic/partner originators → Ultragenyx (development + some internal gene-therapy manufacturing + CMOs) → specialty distribution → rare-disease patients via national payers.

Named stakeholders along the chain:

• Upstream IP / co-development partners: Kyowa Kirin (Crysvita — co-develops and now commercializes the Profit-Share Territory), Regeneron (Evkeeza license), Mereo BioPharma (setrusumab/UX143 license + a Dec-2024 manufacturing & supply agreement), GeneTx Biotherapeutics + Texas A&M University (GTX-102/apazunersen; TAMU license carries milestone + PRV economics), Dimension Therapeutics (acquired — source of DTX301/DTX401 gene-therapy IPR&D).
• Manufacturing: internal AAV gene-therapy facility + third-party CMOs for drug substance/product; CMC (chemistry/manufacturing/controls) spend is spread across gene-therapy programs and is a recurring R&D cost.
• Financial counterparties (royalty buyers — a supply-chain-of-capital chokepoint, see Lens 10): RPI Finance Trust (an affiliate of Royalty Pharma) and OCM LS23 Holdings LP (an OMERS vehicle) have bought slices of future Crysvita royalties.

Chokepoints / single-source dependencies:

• Crysvita commercial control sits with KKC, not Ultragenyx — Ultragenyx is a revenue-share recipient on its single largest stream and does not control the commercial engine. That is the defining supply-chain dependency.
• Gene-therapy CMC is the binary manufacturing chokepoint — the UX111 Complete Response Letter (July 2025) was CMC-related, not efficacy (see Lens 5/10). For AAV gene therapies, manufacturing is the approval risk.
• Rare-disease patient identification itself is a structural bottleneck the company repeatedly flags — revenue depends on finding and diagnosing tiny patient pools.

supply-chain.md commercial-layer file is missing (genomics wiki not yet compiled), so the chain above is filing-derived.

Lens 3 · Competitive Advantages (moats)

Real moats:

• Orphan/rare-disease regulatory moat. Each approved product holds orphan-drug exclusivity, and many candidates carry Breakthrough Therapy, Fast Track, RMAT, Rare Pediatric Disease, and PRIME designations. In rare disease, being the only approved therapy for a defined genetic indication is the moat — Crysvita is "the only approved treatment that addresses the underlying cause of XLH."
• Execution/know-how moat. The durable edge is institutional: rare-disease patient identification, ultra-small-trial design, and accelerated-approval regulatory strategy. Kakkis literally helped write the accelerated-approval reform (FDASIA 2012, via his EveryLife Foundation) — see Lens 9. Counterparties in-license to Ultragenyx because of this reputation.
• Pediatric Priority Review Vouchers (PRVs) — gene-therapy approvals in rare pediatric disease can mint tradeable PRVs (each historically worth ~$100M+).

Bargaining power — mixed:

• Over payers: high, per drug — single approved therapy for a fatal/morbid genetic disease commands premium orphan pricing.
• Over its biggest partner: weak. Ceding Crysvita commercialization to KKC and selling royalties forward to Royalty Pharma/OMERS both signal Ultragenyx is the price-taker on its franchise economics. It traded long-term upside for near-term cash.

positioning.md/bottlenecks.md missing — moat read is filing + reasoning, not commercial-layer-grounded.

Lens 4 · Segments

The 10-K reports revenue by product (no operating-income-by-segment breakout; the company runs as one operating segment):

All ``. Trend = accelerating product sales (+29%) but decelerating royalty (+11%). The growth driver is the directly-sold product portfolio — Evkeeza (EMEA/Japan launch, +84%) and Crysvita LatAm product sales (more patients on therapy). The royalty line is maturing. Geographic split is not tabulated by segment, but management attributes product growth to LatAm (Crysvita) and EMEA/Japan (Evkeeza). segments.csv empty on disk → numbers taken from the filing's MD&A table.

---

Phase B — Measure performance (+clinical overlay: Lens 5 = latest print + pipeline-by-phase; Lens 7 = comps + catalyst calendar)

Lens 5 · Earnings Result (latest print: Q1 2026, filed 2026-05-06) + Pipeline-by-phase

The print:

• Revenue dipped YoY (−2%) — a soft top line for a "growth" biopharma; full-year guidance (reaffirmed) is $730–760M (vs $673M FY25, implying ~8–13% growth weighted to H2).
• Headline R&D rose to $187M, but that includes a $28M one-time restructuring charge ($30M total restructuring: $28M in R&D + $2M SG&A). Underlying R&D ≈ $159M, down ~4% YoY — the cut is real but masked in the headline. Read the headline carefully: the loss widened to $185M even as the company restructures.
• Cash: $534M at Mar-31-2026, down from $737M at Dec-31-2025 — a $203M single-quarter drawdown. This is the most important number in the dossier (see Lens 11 runway).
• Market reaction: the stock ROSE on the print despite the wider loss — the market traded the reaffirmed 2026/2027 guidance + the two H2 FDA catalysts, not the Q1 P&L.

Pipeline by phase (the +clinical overlay — the asset table is the company):

The standout: UX143 was 20% of FY25 R&D ($147M of $750M) and was the single largest pipeline bet — and it missed. The growth narrative now rests on UX111 + DTX401 (both gene therapies, both with H2-2026 PDUFA dates) and GTX-102 Angelman (H2-2026 readout).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty). From the public Q1-2026 call:

• Management framing is defensive-but-confident: reaffirmed FY2026 revenue ($730–760M) and the 2027 profitability goal despite the widening loss. The deliberate message: "the setrusumab failure does not break the path to profitability; the cost base is being cut and the approvals are coming."
• Recurring focus: cash discipline (the ~10% workforce cut, curtailing UX143 manufacturing), 2027 break-even, and de-risking UX111/DTX401 through approval.
• What they stopped saying: the bullish setrusumab/OI commentary that dominated prior calls (Kakkis: "surprised and disappointed"). The OI blockbuster narrative is gone.
• Tone shift over time: from "broad late-stage portfolio, multiple shots on goal" (early 2025) → "focus resources on the highest-value drivers, cut everything else" (Feb–May 2026). A classic pivot from expansion to survival-to-profitability.

Lens 7 · Comps + Catalyst calendar

Peer table — rare-disease / genetic-medicine specialists (P/E n/a — all are loss-making or lumpy; rare-disease names are valued on P/S and pipeline rNPV, not earnings multiples):

Provenance: market caps and revenues with dates; **P/S ratios = mkt cap ÷ FY2025 revenue, arithmetic shown** (e.g. RARE $2.43B ÷ $673M = 3.6x; on the reported ~$2.2B cap, 3.3x). EV/Sales, EV/EBIT, P/E, dividend yield, 5-yr avg ROE were not sourced to a reliable feed — n/a rather than fabricated. RARE pays no dividend; ROE is meaningless on persistent net losses + negative equity.

Read: RARE at ~3.3–3.6x sales sits below BioMarin (the mature analog at 3.7x) and far above Sarepta (0.8x, broken by safety). The market is pricing RARE as "BioMarin-lite with binary upside" — neither a value name nor a momentum name. The dispersion in analyst targets ($25 → $128, median ~$58.50) is the thesis: this is a catalyst-binary stock, not a re-rating-on-fundamentals stock.

Catalyst calendar (the +clinical lens):

Lens 8 · Stock-Price Catalysts (what actually moves RARE)

The tape says RARE is driven by binary clinical/regulatory events, not earnings:

• Dec 29, 2025: −44.6% in one day (to $18.93), ~$1B market value erased, on the setrusumab Ph3 dual miss. The single most violent move in the window.
• 52-week range $18.29–$42.37 — the high ($42.37, Jul-2025) predates the setrusumab failure; the low ($18.29, Mar-2026) is the post-failure capitulation. The stock roughly halved on one trial.
• July 2025: UX111 CRL (CMC) — a negative regulatory surprise.
• May 2026: Q1 print → stock UP on guidance reaffirmation, not the loss.

Pattern: RARE reacts almost entirely to pipeline readouts and FDA decisions, asymmetrically to the downside on failures. Quarterly revenue barely moves it. This is a pure event-driven, binary-catalyst name — which dictates how any position must be sized and timed.

---

Phase C — Judge people & books (+clinical overlay: Science & exclusivity bolt-on)

Lens 9 · Management

CEO/Founder Emil Kakkis, M.D., Ph.D. — one of the most credentialed operators in rare disease:

1. Track record (quantified, genuine pedigree): MD/PhD geneticist (UCLA Medical Scientist Program). At Harbor-UCLA he developed the enzyme-replacement therapy concept that became Aldurazyme (MPS I, FDA-approved 2003). At BioMarin (1998–2009) he guided three rare-disease approvals (MPS I, MPS VI, PKU) and contributed to programs in four more indications. This is a man who has actually shipped rare-disease drugs before Ultragenyx — rare for a biotech founder-CEO.
2. Tenure & skin in the game: Founder, CEO since 2010 (16 years), took it public 2014. Insider-ownership figure not on disk (insider-transactions.csv absent) — n/a; founder-CEO of 16 years implies meaningful alignment but quantify before relying on it.
3. Capital-allocation history — the honest mixed verdict: Built four approved products from in-licensed assets (good capital efficiency for the model). BUT chronic dilution (weighted shares 73.5M→90.5M→98.6M→100.6M, +37% in three years ) and selling future Crysvita royalties to RPI/OMERS — financing the burn by mortgaging the best asset. ROE/ROIC are negative throughout (persistent losses). Capital allocation is "fund the pipeline at almost any cost" — vindicated only if UX111/DTX401 land.
4. Red flags: One immaterial related-party item — a $1M contribution (2022–2026) to a non-profit foundation on whose board Kakkis sat; fully expensed, no further obligation. Minor, disclosed, concluded. No promotional-behavior or comp red flags surfaced.
5. Archetype: mission-driven scientific founder, not a financial operator. The EveryLife Foundation (he founded it; it drove FDASIA accelerated-approval reform in 2012) shows a regulatory-policy strategist. Implication: brilliant at getting rare drugs approved; the open question is whether he can hit a hard financial target (2027 profit) when it conflicts with funding more science — the Q1 R&D line (still rising ex-restructuring's reversal) hints the instinct is to keep spending.

Lens 10 · Forensic Red Flags

Forensic-analyst read of the accounting:

• NEGATIVE STOCKHOLDERS' EQUITY: −$236M at Mar-31-2026 (vs −$80M at Dec-31-2025); accumulated deficit $4,717M. The deficit is mechanical (16 years of R&D losses) but the negative equity is amplified by the royalty-monetization structure below. Total assets $1,296M.
• Royalty monetization = the central accounting feature to understand. Ultragenyx sold future Crysvita royalties to RPI (Royalty Pharma affiliate, July 2022) and OMERS (Nov 2025, $392M net proceeds). Accounting consequence: it records a "liability for sales of future royalties," then books non-cash royalty revenue prospectively and non-cash interest expense against the liability ($62M FY25; $21M in Q1'26 alone). So a chunk of reported "royalty revenue" is non-cash (it's already been sold for upfront cash), and the interest line is non-cash. Quality-of-revenue flag: headline revenue includes non-cash royalty that does not convert to fresh cash — the real cash-generative product line is the $369M of product sales, not the full $673M. This is legitimate, disclosed, and common in biopharma, but it inflates the optics of the top line and the loss.
• Cash flow vs. earnings: FY25 net loss $575M; cash used in operations $466M. The gap is non-cash royalty revenue, non-cash interest, and SBC ($84M R&D SBC alone). Cash burn is lower than the GAAP loss — but still ~$466M/yr against $534M cash.
• SBC is heavy: ~$84M R&D SBC + more in SG&A; ~$30M SBC in Q1'26. Standard for biopharma; flatters nothing here since the company reports GAAP losses.
• Intangibles / IPR&D: IPR&D for DTX301/DTX401 (from the Dimension acquisition) + Dojolvi/Evkeeza license intangibles, tested annually; no impairments through Dec-31-2025. Watch: if UX143 (or a gene-therapy program) is abandoned, expect a non-cash IPR&D write-off.
• No revenue-recognition or receivables/inventory red flags beyond ordinary timing — AR rose on sales-timing, inventory built ahead of launches.

Regulatory findings (required sub-section):

• SEC Litigation Releases: none. 0 LRs naming Ultragenyx (EDGAR EFTS, 2021-2026).
• SEC AAERs: none. 0 accounting/auditing enforcement releases.
• 10-K Item 3 (Legal Proceedings): the company states it is not currently a party to any material legal proceedings, facing only ordinary-course claims.
• Non-SEC (FDA/DOJ/FTC) web search: the only material "regulatory" events are drug-development outcomes, not enforcement — the UX111 CRL (CMC, July 2025) and the setrusumab Ph3 miss (Dec 2025). No consent decrees, fines, or penalties surfaced.
• Conclusion: No material regulatory or legal enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-22. The risks here are clinical and financial, not legal/forensic.

Science & exclusivity bolt-on (+clinical): Mechanism validation is strongest for the approved products and DTX401 (positive Ph3) and weakest, now, for the anti-sclerostin OI thesis (setrusumab failed despite raising BMD — proving the mechanism moved bone density but not fractures, a cautionary read-through). UX111's risk is manufacturing (CMC), not biology. IP/orphan exclusivity is the protective layer; gene-therapy programs carry RMAT/Breakthrough designations. KOL credibility flows from Kakkis himself.

---

Phase D — Project & stress-test (+clinical overlay: Lens 11 = runway-to-catalyst)

Lens 11 · Forward Projection + Runway-to-Catalyst

Ultragenyx is loss-making and guides to profitability in 2027, so the meaningful projection is not an EPS curve — it is (a) does cash reach the catalysts, and (b) is the 2027 profit credible. No forecast.ts logged (watchlist/breadth mode; see SKILL).

Runway-to-catalyst — the crux:

• Cash $534M (Mar-31-2026). FY25 operating cash burn $466M ≈ ~$117M/quarter.
• Pure operating runway ≈ $534M ÷ $117M/q ≈ 4.6 quarters ≈ ~1.1 years — i.e. into roughly mid-2027 on operations alone, before any new financing or revenue inflection.
• Management asserts existing capital funds "at least the next 12 months" — consistent with the arithmetic, but tight: it lands the company right at the 2027 profitability target with little margin. The Q1 $203M cash drop (which included financing/investing timing) overstates the steady-state burn, but even the clean ~$117M/q op burn leaves little buffer if the H2-2026 approvals slip or launches disappoint.

Revenue path (base/bull/bear), bottom-up from guidance [base inputs: FY26 guide $730–760M; FY25 $673M actual — research-layer/web]:

• Base (~$745M FY26, then double-digit growth FY27): product sales keep compounding (~+20%/yr on Evkeeza/Crysvita-LatAm) + one of {UX111, DTX401} approves and begins a 2027 ramp; R&D+SG&A down ≥15% in 2027 per guidance → company reaches GAAP break-even / small profit in 2027 as guided. EPS turns from −$5.83 (FY25) toward ~breakeven by FY27.
• Bull (~$760M+ FY26, accelerating FY27): both UX111 + DTX401 approve, GTX-102 Angelman Ph3 hits → three new launches + a PRV monetization (~$100M+ one-time). 2027 profit comfortably, and the multiple re-rates toward BioMarin+. Analyst high target $128 lives here.
• Bear (≤$700M FY26, flat-to-down FY27): a second pipeline setback (UX111 CRL #2 on CMC, or DTX401 CRL, or GTX-102 miss) → 2027 profitability slips, cash dips below comfort, a dilutive raise at a depressed price (more shares onto the +37%/3yr trend), and the stock revisits the $18 low. Analyst low target $25 lives here.

The whole equity is a weighted bet on the H2-2026 catalyst slate clearing AND the cost base actually falling ≥15% in 2027. Miss either and "profitability 2027" breaks.

Lens 12 · Bull vs Bear

Bull case (narrative): Ultragenyx is the rare-disease compounding machine the market has temporarily written off because one (overweighted) bet failed. Four approved products grew revenue +20% to $673M and are still accelerating on Evkeeza/Crysvita-LatAm. Behind them sit two Priority-Review gene therapies with PDUFA dates eight weeks apart (DTX401 Aug 23, UX111 Sep 19) — UX111 would be the first therapy ever approved for Sanfilippo A, an unmet-need monopoly. The CEO is a proven rare-disease drug-shipper (3 approvals at BioMarin). The cost base is being cut to hit a hard 2027 profitability target, and at ~3.3x sales the stock is cheaper than its mature analog BioMarin while carrying more near-term optionality. The market is over-anchored on setrusumab and under-pricing two imminent approvals.

Bear case (narrative): This is a serial diluter that just lost its biggest pipeline bet, runs negative stockholders' equity, has already sold its best asset's royalties forward for cash, and is burning ~$466M/yr against ~$534M of cash — i.e. ~1 year of self-funding before it must either hit a never-before-achieved profit or dilute again. Setrusumab failing despite moving bone-mineral-density is a warning that this team's late-stage reads can be wrong on the endpoints that matter. UX111 has already been rejected once (CMC) — gene-therapy manufacturing is exactly where Ultragenyx's CRL came from. Three binary events in H2-2026 is three ways to miss.

Pre-mortem (it's Dec 2027, the thesis broke — what happened?): Most likely path — UX111 got a second CRL (CMC issues are sticky) and/or DTX401's launch was slow (gene-therapy uptake/reimbursement is hard), 2027 profitability slipped to "2028+," cash fell under $250M, and the company raised equity at ~$15–18, crystallizing dilution. Setrusumab was formally wound down with an IPR&D write-off. The stock sat in the high-teens.

Are multiples too high? At ~3.3–3.6x sales for a loss-making, negative-equity name with a maturing royalty and one big recent failure, the multiple is not cheap on fundamentals — it is entirely a call option on the H2-2026 catalysts. Fair only if you underwrite ≥1 approval.

Contrarian view (what the market refuses to see): Both sides over-index on setrusumab. The under-appreciated fact is the royalty-monetization machine has quietly de-risked the balance sheet's cash needs ($392M from OMERS in Nov-2025) — Ultragenyx engineered runway through the failure. If even one of UX111/DTX401 approves, the "going-concern-adjacent" narrative flips to "profitable rare-disease platform" almost overnight, and 3.3x sales will look like a gift. The bet is binary, but the downside is partly pre-funded.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the model: the single largest revenue stream (Crysvita) is controlled by KKC and already partly sold to Royalty Pharma/OMERS — Ultragenyx is a revenue-share recipient on a maturing annuity it has mortgaged, not the owner of a growing franchise. The "growth" is small directly-sold products plus hope.
• Revenue concentration: Crysvita (product + royalty) is ~$481M of $673M = ~71% of revenue tied to one molecule whose commercialization Ultragenyx doesn't run and whose royalties it has sold forward. If XLH patient growth plateaus or a competitor emerges, the base erodes.
• Why the moat is weaker than bulls think: orphan exclusivity protects approved products, but the equity value is in unapproved candidates — and the company just proved (setrusumab) that late-stage rare-disease bets fail even with good Phase 2 data and a "clear biology" thesis.
• Most dangerous competitor bulls underestimate: in gene therapy, the competitor is the FDA's CMC bar itself (and AAV manufacturing complexity) — UX111's CRL shows the chokepoint is internal/regulatory, not a rival.
• Worst capital-allocation moves: funding the burn via +37% share dilution in 3 years and selling future Crysvita royalties — both transfer long-term value out to fund near-term science. A short would call this value leakage.
• Assumptions that must hold for today's price: (1) ≥1 of UX111/DTX401 approves on schedule; (2) the cost base actually falls ≥15% in 2027; (3) no dilutive raise at a low price. All three must hold.
• If growth disappoints 20–30%: with negative equity and ~1yr cash, a revenue miss + a catalyst slip forces a dilutive raise → the stock revisits $18 or lower; the bear analyst target is $25.
• Single scenario that permanently impairs: a second UX111 CRL plus a DTX401 setback in the same window — back-to-back gene-therapy approval failures would gut the pipeline narrative, force a raise from a position of weakness, and re-rate RARE toward Sarepta's broken 0.8x sales. Plausibility: moderate (CMC issues recur; two independent approvals both clearing is not certain) — this is the real tail risk, not fraud.

Lens 14 · Management Questions (ordered by information value)

1. UX111 was rejected on CMC grounds — precisely what changed in the manufacturing/comparability package in the resubmission, and why are you confident the same issue won't recur at the Sep-19 PDUFA?
2. Walk us through the 2027 profitability bridge line by line: how much of it is the ≥15% opex cut vs. new-product revenue, and what revenue floor must the four approved products + any approvals hit for it to be GAAP-positive?
3. With ~$534M cash and ~$117M/quarter operating burn, what is your minimum acceptable cash balance, and under what scenario do you raise equity vs. monetize more royalties vs. cut deeper?
4. After setrusumab raised BMD but failed on fractures — what did that teach you about your endpoint-selection and Phase-2-to-3 translation, and how does it change how you read GTX-102's Angelman data?
5. Is setrusumab dead, and if so when do you take the IPR&D/asset write-off — or is there a credible regulatory path on the secondary endpoints?
6. You've sold Crysvita royalties twice (RPI, OMERS) — how much future Crysvita economics remain unsold, and is further royalty monetization part of the funding plan?
7. For DTX401 (PDUFA Aug 23) — what is your launch and reimbursement readiness for a one-time gene therapy in GSDIa, and what's a realistic 2027 revenue contribution?
8. What share-count dilution should holders model through 2027 across ATM, options, and any raise — i.e. how much more dilution is "in the plan"?
9. Crysvita is ~71% of revenue and KKC controls its commercialization — how do you grow the franchise you don't run, and what's the XLH/TIO patient-growth ceiling?
10. Which single late-stage program, if it failed, would most damage the 2027–2030 plan — and what's your contingency?
11. GTX-102 Angelman is the largest TAM in the pipeline — what efficacy bar on the Ph3 Aspire readout (H2-2026) constitutes a clear win vs. an ambiguous result?
12. What is insider ownership today, and have executives been net buyers since the December selloff?
13. How do you think about PRV monetization (UX111/DTX401) as a one-time cash source, and is it baked into the 2027 plan?
14. With four products and a cut cost base, would you consider being acquired — is BioMarin-style consolidation on the table, or is independence non-negotiable?
15. What is the most important thing the market currently misunderstands about Ultragenyx's risk profile?

---